首页 > 市场调查报告书 > 製药

疼痛

偏头痛药物市场规模、份额和成长分析（按治疗方法、治疗领域、给药途径和地区划分）－2026-2033年产业预测

市场调查报告书

商品编码

1896791

偏头痛药物市场规模、份额和成长分析（按治疗方法、治疗领域、给药途径和地区划分）－2026-2033年产业预测

Migraine Drugs Market Size, Share, and Growth Analysis, By Treatment Class, By Therapeutic Class, By Route of Administration, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月23日 | 出版商:

SkyQuest | 英文 207 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，偏头痛药物市场规模将达到 53.1 亿美元，到 2025 年将成长至 62.7 亿美元，到 2033 年将成长至 235.5 亿美元，在预测期（2026-2033 年）内复合年增长率为 18%。

偏头痛药物市场主要集中在旨在缓解或预防偏头痛症状的药物，并分为急性治疗和预防性治疗两大类。急性药物用于治疗最近一次偏头痛发作，而预防性治疗则旨在降低严重发作的频率。推动市场成长的因素包括：人们对有效预防方案的认识不断提高、诊断能力的进步以及创新治疗方法的引入。然而，新型治疗方法的高成本和潜在副作用阻碍了市场成长，并可能导致医疗服务提供者和患者犹豫不决。儘管面临这些挑战，但由于药物研发的进步、个人化医疗的兴起以及新兴市场机会的不断扩大，预计该市场仍将实现显着成长。

偏头痛药物市场驱动因素

偏头痛药物市场的主要驱动力是CGRP拮抗剂和抑制剂等创新药物的出现，这些药物代表了偏头痛治疗的突破。这些新疗法采用复杂的作用机制，已被证明能有效降低偏头痛的强度和发作频率，从而进一步推动了市场扩张。此外，对偏头痛根本原因的持续研究也催生了更先进的治疗方案。对偏头痛遗传和分子基础的深入了解正在推动个人化治疗的发展，为这种令人痛苦的疾病的个人化管理铺平了道路。

限制偏头痛药物市场的因素

偏头痛药物市场面临许多挑战，包括患者对某些药物的不满意和接受度低，这主要是由于治疗效果因人而异。这种差异可能导致患者寻求他们认为更有效的替代疗法。此外，一些新型治疗方法会产生副作用，影响患者的生活品质。因此，患者可能会被迫停止使用这些药物，或需要服用其他药物来控制副作用。诸如此类的问题凸显了市场的复杂性，并强调了偏头痛治疗需要更个人化的方法。

偏头痛治疗市场趋势

偏头痛治疗市场正经历着向CGRP抑制剂的显着转变。这些药物正迅速成为患者和医疗保健提供者的首选。诸如Aimovig、Emgality和Ajovy等创新治疗方法已显示出显着疗效，能够降低偏头痛发作的频率和强度，并正被慢性偏头痛患者广泛接受。这些药物的优势在于其个人化的给药方案，允许每月或每季给药，从而提高患者的依从性和生活品质。随着人们对偏头痛严重影响的认识不断提高，对CGRP抑制剂等有效预防性治疗的需求预计将进一步增长。

北美洲
- 美国
- 加拿大
欧洲
- 英国
- 德国
- 西班牙
- 法国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2021-2023年营收年比比较

主要企业简介

Pfizer
GlaxoSmithKline
Allergan
Amgen
Eli Lilly
Teva Pharma
Biohaven Pharma
Johnson & Johnson
Valeant Pharma
AbbVie Inc
Eli Lilly and Company
Novartis International AG
Novartis International AG
Biohaven Pharmaceuticals
Boehringer Ingelheim
Zynerba Pharmaceuticals
Teva Pharmaceutical
Hoffmann-La Roche Ltd
Amgen
AstraZeneca

结论与建议

简介目录

Product Code: SQMIG35I2350

Migraine Drugs Market size was valued at USD 5.31 Billion in 2024 and is poised to grow from USD 6.27 Billion in 2025 to USD 23.55 Billion by 2033, growing at a CAGR of 18% during the forecast period (2026-2033).

The migraine drugs market is focused on medications designed to alleviate or prevent migraine symptoms, categorized into acute and preventive treatments. Acute medications address recent migraine attacks, while preventive options aim to reduce the frequency of severe episodes. The market is propelled by heightened awareness of effective preventive solutions, advancements in diagnostic capabilities, and the introduction of innovative therapies. However, growth is hindered by the high cost of new treatments and potential side effects, which can lead to hesitancy among healthcare providers and patients. Despite these challenges, the market is poised for significant growth, driven by advancements in drug development, a shift towards personalized medicine, and expanding opportunities in emerging markets.

Top-down and bottom-up approaches were used to estimate and validate the size of the Migraine Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Migraine Drugs Market Segments Analysis

Global Migraine Drugs Market is segmented by Treatment, Therapeutic Class, Route of Administration, Age Group, Availability and region. Based on Treatment, the market is segmented into Acute, Preventive. Based on Therapeutic Class, the market is segmented into CGRP monoclonal antibodies, CGRP small molecule antagonists, Acetylcholine inhibitors/ neurotoxins, Triptans, Ditans, Ergot alkaloids, NSAIDs, Others. Based on Route of Administration, the market is segmented into Oral, Injectable, Others. Based on Age Group, the market is segmented into Pediatric, Adult, Geriatric. Based on Availability, the market is segmented into Prescription Drugs, Over-the-Counter (OTC) Drugs. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Migraine Drugs Market

The Migraine Drugs market is significantly driven by the emergence of innovative drug classes such as CGRP gepants and inhibitors, which symbolize substantial advancements in migraine treatment. These new therapies employ precise mechanisms that have demonstrated their effectiveness in reducing both the intensity and occurrence of migraines, further stimulating market expansion. Additionally, ongoing research into the underlying causes of migraines is leading to the creation of advanced therapeutic options. Enhancements in understanding the genetic and molecular foundations of migraines are facilitating the rise of personalized treatments, setting the stage for a more tailored approach to managing this debilitating condition.

Restraints in the Migraine Drugs Market

The Migraine Drugs market faces significant challenges, as the efficacy of various treatments can vary widely among patients, leading to dissatisfaction and decreased acceptance of certain medications. This variability may prompt individuals to seek alternative therapies that they perceive as more effective. Additionally, some new treatments are associated with side effects that can hinder patients' quality of life, causing them to either stop using these medications or rely on additional drugs to manage adverse reactions. Such issues highlight the complexities within the market and underscore the need for more personalized approaches in migraine treatment.

Market Trends of the Migraine Drugs Market

The migraine drugs market is experiencing a significant shift toward CGRP inhibitors, which have rapidly emerged as a preferred choice for both patients and healthcare providers. These innovative treatments, exemplified by products such as Aimovig, Emgality, and Ajovy, demonstrate remarkable efficacy in reducing the frequency and intensity of migraines, leading to increased acceptance among chronic sufferers. The appeal of these medications lies in their personalized dosing regimen, allowing for monthly or quarterly administration that enhances patient compliance and quality of life. As awareness of migraine's debilitating impact grows, the demand for effective preventive treatments like CGRP inhibitors is expected to flourish.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Driver & Opportunities
- Restraints & Challenges
Porters Analysis & Impact
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Technological Advancement
Regulatory Landscape
Patent Analysis
Value Chain Analysis
Case Study Analysis
PESTEL Analysis
Macro-Economic Indicators
Trade Analysis
Market Attractiveness Index
Supply Chain Analysis
Pricing Analysis

Global Migraine Drugs Market Size by Treatment & CAGR (2026-2033)

Acute
Preventive

Global Migraine Drugs Market Size by Therapeutic Class & CAGR (2026-2033)

CGRP monoclonal antibodies
CGRP small molecule antagonists
Acetylcholine inhibitors/ neurotoxins
Triptans
Ditans
Ergot alkaloids
NSAIDs
Others

Global Migraine Drugs Market Size by Route of Administration & CAGR (2026-2033)

Oral
Injectable
Others

Global Migraine Drugs Market Size by Age Group & CAGR (2026-2033)

Pediatric
Adult
Geriatric

Global Migraine Drugs Market Size by Availability & CAGR (2026-2033)

Prescription Drugs
Over-the-Counter (OTC) Drugs

Global Migraine Drugs Market Size & CAGR (2026-2033)

North America, (Treatment, Therapeutic Class, Route of Administration, Age Group, Availability)
- US
- Canada
Europe, (Treatment, Therapeutic Class, Route of Administration, Age Group, Availability)
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific, (Treatment, Therapeutic Class, Route of Administration, Age Group, Availability)
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
Latin America, (Treatment, Therapeutic Class, Route of Administration, Age Group, Availability)
- Brazil
- Rest of Latin America
Middle East & Africa, (Treatment, Therapeutic Class, Route of Administration, Age Group, Availability)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

Pfizer
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Allergan
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biohaven Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Valeant Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis International AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis International AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biohaven Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zynerba Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hoffmann-La Roche Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments